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BACKGROUND: High levels of S100A6 have been associated with poor outcome in pancreatic cancer patients. The functional role of
S100A6 is, however, poorly understood.
METHODS: Immunoprecipitation followed by two-dimensional gel electrophoresis and mass spectrometry were undertaken to identify
S100A6 interacting proteins in pancreatic cancer cells. Immunohistochemistry and coimmunofluorescence were performed to
examine expression or colocalisation of proteins. siRNA was used to deplete specific proteins and effects on motility were measured
using Boyden Chamber and wound healing assays.
RESULTS: Our proteomic screen to identify S100A6 interacting proteins revealed annexin 11, annexin 2, tropomyosin b and a
candidate novel interactor lamin B1. Of these, annexin 2 was considered particularly interesting, as, like S100A6, it is expressed early
in the development of pancreatic cancer and overexpression occurs with high frequency in invasive cancer. Reciprocal
immunoprecipitation confirmed the interaction between annexin 2 and S100A6 and the proteins colocalised, particularly in the
plasma membrane of cultured pancreatic cancer cells and primary pancreatic tumour tissue. Analysis of primary pancreatic cancer
specimens (n¼55) revealed a strong association between high levels of cytoplasmic S100A6 and the presence of annexin 2 in the
plasma membrane of cancer cells (P¼0.009). Depletion of S100A6 was accompanied by diminished levels of membrane annexin 2
and caused a pronounced reduction in the motility of pancreatic cancer cells.
CONCLUSION: These findings point towards a functional role for S100A6 that may help explain the link between S100A6 expression in
pancreatic cancer and aggressive disease.
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Pancreatic ductal adenocarcinoma is a leading cause of cancer-
related deaths in the United States and Europe (Parkin et al, 2005;
Jemal et al, 2008). The disease is characterised by rapid invasion
which, combined with late diagnosis and ineffective treatment,
leads to a dismal prognosis. The majority of patients die within
1 year of diagnosis (Ghaneh et al, 2007). A number of proteins
of the S100 family, including S100A2, S100A4, S100A6, S100A11
and S100P have been shown to be overexpressed in pancreatic
cancer (Crnogorac-Jurcevic et al, 2003; Shekouh et al, 2003;
Vimalachandran et al, 2005; Ohuchida et al, 2006, 2007a). In many
cases, overexpression has been associated with enhanced invasion
(Ohuchida et al, 2005; Suemizu et al, 2007; Whiteman et al, 2007)
or poorer outcome (Vimalachandran et al, 2005; Oida et al, 2006;
Ohuchida et al, 2007a). Virtually all S100 proteins act as Ca
2þ
sensors. They participate in Ca
2þ signal transduction by binding
and modifying the activities of specific target proteins. They are
expressed in a cell-specific manner, and they regulate a large
variety of intracellular activities. Some S100 proteins are secreted
and a number have been shown to bind the receptor for advanced
glycation end products (Donato, 2007; Heizmann et al, 2007).
Several studies have identified overexpression of S100A6 in
pancreatic cancer (Crnogorac-Jurcevic et al, 2003; Logsdon et al,
2003; Shekouh et al, 2003), in PanIN lesions (Vimalachandran
et al, 2005) and in intraductal papillary mucinous neoplasms
(Ohuchida et al, 2007b). Moreover, high level expression has been
linked to poor outcome (Vimalachandran et al, 2005). A functional
role for S100A6 in pancreatic cancer has, nevertheless, remained
elusive. Ohuchida et al (2005) showed decreased invasion of
pancreatic cancer cells after depletion of S100A6, although the
means by which S100A6 influences invasion is unclear. To identify
possible mechanisms underlying S100A6 activity, we undertook an
unbiased proteomic screen for the detection of S100A6 interacting
proteins in pancreatic cancer cells. This process involved a combi-
nation of immunoprecipitation, two-dimensional gel electro-
phoresis (2-DE) and mass spectrometry and revealed annexin 11,
annexin 2, tropomyosin b as well as a novel candidate interactor,
lamin B1. The functional roles of annexin 11 and lamin B1 are
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srelatively poorly understood. By contrast, annexin 2 and tropo-
myosin have been much studied and have roles in cytoskeletal
organisation and regulation of actin dynamics (Gerke et al,
2005; Gunning et al, 2008). We chose to focus further studies on
annexin 2 as, like S100A6 (Vimalachandran et al, 2005) it is
also overexpressed in preneoplastic pancreatic lesions (Sitek et al,
2005; Esposito et al, 2006) and is expressed in a similarly high
proportion (480%) of invasive cancers (Paciucci et al, 1998;
Chen et al, 2005; Ortiz-Zapater et al, 2007). We report here
colocalisation of annexin 2 and S100A6 in the plasma membrane
of cultured pancreatic cancer cells and pancreatic tumours.
Moreover, we report that membranous annexin 2 expression
was more frequently observed in primary pancreatic tumours
when cytoplasmic S100A6 levels were high (P¼0.009) and that
knockdown of S100A6 was accompanied by a reduction in cells
expressing membranous annexin 2. These observations prompted
us to investigate whether S100A6 contributed to motility in
pancreatic cancer cells. We show here for the first time that
depletion of S100A6 has a profoundly negative effect on the
motility of pancreatic cancer cells. This finding may help explain
the association of S100A6 with aggressive disease.
MATERIALS AND METHODS
Cell lines
The human pancreatic cancer cell lines Panc-1, MiaPaCa-2 and
Suit-2 were maintained in RPMI 1640 medium supplemented with
10% fetal calf serum, 2mML-glutamine, 2500iuml
 1 penicillin and
5mgml
 1 streptomycin (all from Sigma, Poole, UK) at 371Ci na
humidified atmosphere of 5% CO2.
Immunoprecipitation
Panc-1 cells were washed twice with PBS, resuspended in SLIP
buffer (50mM Hepes, pH 7.5, 150mM NaCl, 10% glycerol, 0.1%
Triton X-100 and 0.5mgml
 1 BSA) supplemented with protease
inhibitors (Roche Diagnostics, Indianapolis, IN, USA) then
sonicated for 15s at 41C. Lysates were clarified by centrifugation
at 16000g for 10min then the protein quantified using a BCA
protein assay kit. For analysis of proteins on relatively large
(18 13cm format) 2-D gels, 8mg protein lysate was precleared by
incubating with Protein G-Sepharose beads (GE Healthcare Life
Sciences, Buckinghamshire, UK) for 2h at 41C followed by
centrifugation for 1min at 16000g. Supernatants were then
incubated with 4mg of anti-S100A6 antibody, 4mg antiannexin 2
antibody or 4mg of isotype control IgG or in the absence of any
antibody (beads alone control) and gently mixed overnight at 41C.
Lysates were incubated with 100ml of prewashed Protein
G-sepharose beads for a further 2h with mixing. The immuno-
precipitates were centrifuged, washed three times with SLIP buffer
and resuspended in 50ml of 2-D lysis buffer (7M urea, 2M
thiourea, 4% 3-[(3-cholamidopropyl) dimethylammonio]-1-pro-
pane sulphonate, 40mM Tris base and 1% dithiothreitol). Samples
were stored at  801C until analysis by 1-D SDS–PAGE (using 15%
Tris/Tricine gels) and western blotting or 2-D gel electrophoresis,
as described below.
Two-Dimensional Gel Electrophoresis and protein
identification
Immunoprecipitated proteins were separated by 2-D gel electro-
phoresis as described earlier (Shekouh et al, 2003; Sheikh et al,
2007). Gel images were captured on a GS-800 gel scanner (BioRad,
Hertfordshire, UK) and analysed using Progenesis software
(NonLinear Dynamics, Newcastle upon Tyne, UK). Protein spots
were excised, destained, trypsin digested and subjected to MALDI-
TOF MS and/or LC-MS/MS as described earlier (Shekouh et al,
2003; Sheikh et al, 2007). Data were again submitted to Mascot and
the NCBI database searched with the MS tolerance set to 1.2Da and
the MS/MS tolerance to 0.6Da, with carbamidomethyl as a fixed
modification.
Small interference RNA-mediated knockdown of S100A6
and annexin 2
For small interference RNA (siRNA) treatment, cells were cultured
in six-well plates at a density of 2 10
5cells per well (Panc-1 and
Suit-2) or 4 10
5cells per well (MiaPaca-2). The medium was
replaced 24h later with antibiotic-free medium and cells were
transfected with siRNA (10nmoll
 1) using Lipofectamine
2000 and Optimem I (both from Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. S100A6-targeting
siRNA molecules: siRNA#1: 50-AGA AGG AGC UCA CCA UUG G-30,
siRNA#2: 50-UUG CAA GGC UGA UGG AAG A-30,s i R N A # 3 :5 0-ACA
AGG ACC AGG AGG UGA A-30,s i R N A # 4 :5 0-GGG CCU UGG
CUU UGA UCU AUU-30, as well as an annexin 2-targeting siRNA:
50-AGA CCA AAG GUG UGG AUG AUU-30 were purchased from
Dharmacon (Dharmacon Inc., Chicago, IL, USA). Three control
siRNAs (10nmoll
 1) were used, including a ‘RISC-free’ siRNA
(sicontrol RISC-free siRNA 1, Dharmacon Inc.) and two non-
targeting siRNAs designated control 1 (sicontrol non-targeting
siRNA 1 from Dharmacon) and control 2 (GGA CGC AUC CUU
CUU AA, a gift from Dr M Boyd, University of Liverpool, Liverpool,
UK). S100A6 levels diminished between 48 and 72h after
transfection with S100A6-targeting siRNAs (all three cell lines)
and remained low out to 120h (not shown).
SDS–PAGE and western blotting analysis
Cell lysates were prepared by extraction into 100mM Tris–HCl
(pH 6.8) containing 2% w/v SDS and a protease inhibitor cocktail
(Complete, Mini, EDTA-free protease inhibitors; Roche Applied
Science, UK). Protein samples were quantified using a BCA protein
assay kit (Perbio Science Ltd, Cramlington, UK) then subjected to
SDS–PAGE (using 15% Tris/Tricine gels). Separated proteins were
transferred to hybond nitrocellulose membranes (Amersham
Biosciences, Bucks, UK). Membranes were then blocked for
1h with PBS containing 0.1% Tween-20 (PBS-T) and 5% milk
(Bio-Rad Laboratories Ltd., Hemel Hempstead, Hertfordshire,
UK). Primary antibodies for detecting S100A6 (DakoCytomation,
C a m b r i d g e s h i r e ,U K ) ,a n n e x i n - 2( A b c a mp l c ,C a m b r i d g e ,U K ) ,a n d
b-actin (clone AC-15, Sigma, Poole, UK) were detected by incubating
membranes with horseradish-peroxidase (HRP)-conjugated second-
ary antibodies (Dako). Bound HRP was visualised using the
enhanced chemiluminescence kit (PerkinElmer Life Sciences,
Bucks, UK).
Motility and invasion assays
Seventy-two hours after transfection with S100A6-targeting siRNA,
annexin 2-targeting siRNA or control siRNA, pancreatic cancer
cells were plated (5 10
4 for Panc-1, 1 10
4 for both MiaPaca-2
and Suit-2) for Boyden Chamber motility assays, conducted over
18h, as described earlier (Thompson et al, 2007). Results are
reported as motility indexes, which represent the number of cells
translocating across the membranes after treatment with control-
or S100A6/annexin 2-targeting siRNAs, expressed as a proportion
of the number translocating in the RISC-free control. For invasion
assays, Matrigel-coated Transwell plates (BD Biosciences, Oxford,
UK) were used. Wound healing assays were performed as
described earlier (Thompson et al, 2007) using cells harvested
72h after treatment with siRNAs. Results were expressed as a
migration index, that is, the distance migrated by siRNA treated
(control or targeted) relative to the distance migrated by RISC-free
control RNA-treated cells.
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The incorporation of [
3H]-thymidine into pancreatic cancer cells
was studied using methods described earlier (Varro et al, 2007).
Seventy-two hours after transfection with S100A6-targeting and
control siRNAs, cells (5 10
4) were cultured in six-well plates
in RPMI-1640 containing 10% FBS. Eighteen hours later, [
3H]-
thymidine (2mCiml
 1; Sigma) was added and cells were incubated
for a further 2h and washed three times with 2ml of
ice cold PBS. Trichloroacetic acid (2ml, 5% in PBS) was added
and dishes were incubated at 41C for 20min. Cells were washed
twice with 2ml of ice-cold ethanol and incubated in 1ml of 0.1M
NaOH for 60min at 601C. Solubilised material was recovered,
10ml of scintillation fluid added, and the radioactivity incorpo-
rated determined using a scintillation counter (Packard 1500
TRI-CARB, Boston, MA, USA). Results were expressed as a proli-
feration index, that is, the [
3H]-thymidine incorporated after
siRNA treatment/[
3H]-thymidine incorporated by RISC-free con-
trol RNA-treated cells. Pancreatic cancer cells (Panc-1, MiaPaca-2
and Suit-2) were plated onto 96-well plates at 5 10
3 cells per well,
72h after transfection with S100A6-targeting and control siRNAs.
After 18h of incubation at 371C, MTT assays were performed as
described earlier (Thompson et al, 2007).
Immunofluorescence and immunocytochemistry
Panc-1 cells (subjected to siRNA treatment or not) were grown on
glass coverslips in RPMI-1640 containing 10% fetal bovine serum.
After 24h of incubation at 371C, cells were washed twice with PBS,
fixed in 2% paraformaldehyde dissolved in PBS, then permeabi-
lised using Triton X-100 (0.1% in PBS). For immunofluorescence,
cells were incubated with a PBS solution containing 2% bovine
serum albumin, then for 1h at 41C with either antibodies against
rabbit polyclonal S100A6 (A5115; Dako, 1:400 dilution) or mouse
monoclonal annexin 2 (ab8146; Abcam, 1:200 dilution). Cells were
then washed with PBS and incubated with Cy3-conjugated mouse
or rabbit IgG and FITC-conjugated rabbit or mouse IgG secondary
antibodies for 1h. DNA was stained with DAPI. Coverslips were
mounted and examined using a Nikon fluorescence microscope.
For immunocytochemistry, after fixation and permeabilisation,
cells were incubated in methanol containing 3% H2O2 for 30min at
room temperature followed by 2% BSA in PBS for 1h at 41C and
overnight incubation at 41C with mouse monoclonal annexin 2
antibody (1:200 dilution in 1% BSA/PBS). After three washes
using PBS, HRP-conjugated secondary antibody, was applied
for 1h at room temperature (Envision kit, DakoCytomation)
followed by treatment with diaminobenzidine as chromogenic
substrate for 5min. Slides were counterstained with hematoxylin,
dehydrated, and mounted with DPX mountant (VWR Interna-
tional, Poole, UK).
Immunohistochemistry of pancreatic cancer tissue
microarrays
Immunohistochemical detection of annexin 2 was undertaken,
using a rabbit polyclonal antibody against annexin 2 (Aguilar et al,
2004), on a pancreatic cancer tissue microarray (TMA) containing
matched duplicate non-malignant (normal ducts) and malignant
(tumour) cores from 79 patients treated at the Royal Liverpool
University Hospital, Liverpool, UK, between 1994 and 2003, as
described earlier (Shekouh et al, 2003; Thompson et al, 2007).
Scoring of the pancreatic cancer TMA was performed by a
pancreatic specialist histopathologist (FC). The information
recorded included the subcellular location of annexin 2 staining,
the intensity of staining (graded 0¼negative; 1¼weak;
2¼moderate; and 3¼strong) and the extent of staining (percen-
tage of cells showing positive immunoreactivity: 0 – 100% of cells).
A score was assigned for each cellular compartment¼the intensity
of staining the percentage of cells stained. To obtain associa-
tions between S100A6 and annexin 2 expression, data were
cross-tabulated and Fisher’s two-sided exact tests applied or
Mann–Whitney U-test performed. All statistical analyses were
carried out using Statview V.5.01. Results were considered
significant for values of Po0.05. S100A6 immunostaining was
undertaken earlier (Vimalachandran et al, 2005).
RESULTS
Identification of S100A6-binding proteins
To identify potential S100A6-binding partners, we immuno-
precipitated S100A6 from Panc-1 cell lysates and separated the
recovered proteins by 2-DE. Protein spots observed on gels after
immunoprecipitation with anti-S100A6 antibody (Figure 1A) but
not on control gels (Figure 1B–D) were identified by MALDI-TOF
mass spectrometry and confirmed by LC-MS/MS (Figure 1E–H;
Supplementary Table 1). The identified proteins included the
known binding partners annexin 11 (Mizutani et al, 1992), annexin
2 (Zeng et al, 1993), and tropomyosin (Golitsina et al, 1996) as well
as a candidate novel interactor lamin B1. As both S100A6 and
annexin 2 are overexpressed in pancreatic cancer, with expression
occurring early in the development of the cancer in both cases
(Sitek et al, 2005; Vimalachandran et al, 2005; Esposito et al, 2006;
Ortiz-Zapater et al, 2007), we focused our attention particularly on
annexin 2.
Reciprocal immunoprecipitation of S100A6 by anti-annexin 2
and colocalisation of S100A6 and annexin 2
The interaction between S100A6 and annexin 2 was further studied
by immunoprecipitation followed by western analysis (Figure 2A
and B). In keeping with the proteomic data (Figure 1), annexin-2
was readily detected (Figure 2A, main panel) by western blotting in
complexes precipitated using an anti-S100A6 antibody (a-S100A6)
from Panc-1 cell lysate. For reference, the detectable levels of
annexin 2 in Panc-1 whole cell lysate are shown, as are the levels
of S100A6 in the precipitated and whole cell lysate samples
(Figure 2A, lower panel). Reciprocal immunoprecipitation with an
annexin 2 antibody (a-ANX-2) followed by western analysis with
an anti-S100A6 antibody revealed the specific detection of S100A6
in complexes precipitated from Panc-1 cell lysate (Figure 2B,
main panel). The levels of annexin 2 in precipitated samples
and, for reference, in whole cell lysates are shown (Figure 2B,
lower panel). Coimmunoflourescence analyses of Panc-1 cells
(Figure 2C) revealed colocalisation of S100A6 and annexin 2 in the
cytoplasm with pronounced colocalisation in the plasma mem-
branes. Colocalisation of S100A6 and Annexin 2 was also observed
in the plasma membranes of paraffin-embedded sections from
primary pancreatic tumour material (Figure 2D, see also
Supplementary Figure 1).
Membranous annexin 2 expression was more frequently
observed in primary pancreatic tumours when cytoplasmic
S100A6 levels were high
We described earlier the expression profile of S100A6 in tumours
from 60 pancreatic cancer patients (Vimalachandran et al, 2005).
To determine whether the overexpression of S100A6 occurred in
tumours, which also overexpressed annexin 2, we investigated the
expression of annexin 2 in this cohort (56 cases had sufficient
material for evaluation). Immunohistochemical staining showed
apical (luminal) membrane staining of annexin 2 in non-neoplastic
ducts from all patients (n¼25), where ducts were present on the
TMA (Figure 2E ii). This was also observed in 78% of tumours
(Figure 2E iii and iv), although less frequently in poorly differen-
tiated tumours, in which only 60% (12 out of 20) of cases scored
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spositively for apical membrane staining, compared with moder-
ately and well-differentiated tumours where 92.5% (25 out of 27)
and 88% (8 out of 9) of cases, respectively, were positive for this
type of staining (w
2 P-value¼0.01). Extensive annexin 2 staining
was also detected in the cytoplasm of 76.3% of tumours (Figure 2E
iii–vi). In 55% of tumours, distinct annexin 2 staining of the entire
cell membrane was observed (Figure 2E v and vi). This type of
staining was dubbed membranous staining. Eighty percentage of
patients scored positively for both annexin 2 and for S100A6
(either cytoplasmic or nuclear), whereas 20% expressed either
Figure 1 Identification of candidate S100A6-binding proteins by combined immunoprecipitation, 2-DE and MS. Two-dimensional gels display proteins
precipitated after incubation of (A) Panc-1 cell lysate, S100A6 antibody and Protein G-sepharose beads (B) Panc-1 cell lysate, isotype antibody and Protein
G-sepharose beads (C) Panc-1 cell lysate and Protein G-sepharose beads (D) Protein G-sepharose beads and S100A6 antibody. The protein spots circled in
(A) were picked and proteins identified by MALDI-TOF MS and LC-MS/MS (E–H).
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Figure 2 Association of S100A6 and annexin 2. (A) Proteins were precipitated from Panc-1 cell lysate using an S100A6 antibody (a-S100A6) or isotype
control (IgG) or beads alone, as indicated, and subjected to immunoblotting analysis with annexin 2 (main panel) and S100A6 (lower panel) antibodies. The
levels of annexin 2 and S100A6 detected in Panc-1 whole lysates (0.5 and 2.0mg) are also shown. (B) Recipricol-immunoprecipitation of proteins from Panc-
1 cell lysate using an annexin 2 antibody (a–ANX-2), isotype control or beads alone followed by immunoblot (using 1 out of 5 of the recovered protein
suspension) with S100A6 (main panel) or annexin 2 (lower panel) antibodies. (C and D) Immunofluorescence images of Panc-1 cells (C) and primary
pancreatic tumour material (D) showing colocalisation, merged images (yellow), of S100A6 (green) and annexin 2 (red). Nuclei were labelled in blue using
DAPI. Images were taken using 100  objective. (E) Immunohistochemical staining of a pancreatic cancer tissue microarray using antiannexin 2 antibody.
(i) Secondary antibody only; (ii) annexin 2 expression in non-neoplastic tissue showing apical membrane staining in a duct; (iii–vi) annexin 2 expression in
malignant tissues showing apical membrane and membranous staining. Scale bars¼45mm. (F) The staining scores for cytoplasmic S100A6 were plotted for
primary tumours that were positive or negative for membranous annexin 2. The P-value shown is for comparison of the median scores of S100A6 for the
positive and negative membranous annexin 2 staining, using the Mann–Whitney U-test.
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sannexin 2 or S100A6 alone. Interestingly, we observed that patients
who expressed membranous annexin 2 had significantly higher
cytoplasmic S100A6 scores (Figure 2F, Mann–Whitney U-test;
P¼0.009. See also Supplementary Figure 2). Associations between
the expression of cytoplasmic or nuclear S100A6 and apical mem-
brane annexin 2 (Mann–Whitney U–test; P¼0.38 and P¼0.97,
respectively) or cytoplasmic annexin 2 (Spearman Rank r¼0.06,
P¼0.51; r  0.17, P¼0.23, respectively) could not be established.
RNAi-mediated depletion of S100A6 results in loss of
annexin 2 from the plasma membrane
To further explore the relationship between the levels of S100A6 and
membranous annexin 2, we examined whether diminishing the
levels of S100A6 in a pancreatic cancer cell line would affect the
overall levels or localisation of annexin 2. After siRNA-mediated
depletion of S100A6 from Panc-1 cells, the overall levels of annexin 2
appeared unchanged (Figure 3A, lanes 5 and 6). Similarly, depleting
annexin 2 did not appear to affect the protein levels of S100A6
(Figure 3A, lane 1). However, the levels of annexin 2 in the plasma
membrane, which were detectable by immunofluoresence
(Figure 3B) or immunocytochemistry (Figure 3C) were markedly
reduced in S100A6-depleted cells. In control-siRNA-transfected
cells, 37% of cells examined (n¼1100; two independent experi-
ments) were devoid of membranous annexin 2 staining. However,
after S100A6 depletion, 59% of cells were found to lack membranous
annexin 2 (n¼862 cells; two independent experiments; P¼0.01).
RNAi-mediated reduction in S100A6 expression
dramatically impaired cell motility
Given the association of S100A6 with annexin 2 and the role of the
latter in actin binding and motility, we questioned whether S100A6
may therefore contribute to the motility of pancreatic cancer cells.
Transfection of Panc-1 cells with four S100A6-targeting siRNAs
effectively reduced S100A6 protein levels (Figure 4A) and caused
a significant reduction in motility, from an average of 65.4%
(S100A6 siRNA#1) to 73.8% (S100A6 siRNA#4) compared with a
non-targeting control siRNA (Po0.037). Similarly, transfection of
MiaPaca-2 and Suit-2 cells with S100A6 siRNA#1 caused depletion
of S100A6 and was accompanied by an average decrease of 73.4
and 64.2% in motility compared with the non-targeting control
siRNA (P¼0.003 and P¼0.03, respectively; Supplementary
Figure 3A and B). Wound healing assays were also undertaken.
Depletion of S100A6 from Panc-1 cells, using four independent
S100A6-targeting siRNAs (Figure 4B), reduced wound healing by
at least 42% in each case compared with control-siRNA-treated
cells (P¼0.03, siRNA#1; P¼0.02, siRNA#2; P¼0.02, siRNA#3;
P¼0.05, siRNA#4). In a similar manner, depletion of S100A6 from
Suit-2 cells using four S100A6-targeting siRNAs (Supplementary
Figure 3C) significantly reduced wound closure (P¼0.002,
siRNA#1, P¼0.05, siRNA#2, P¼0.01, siRNA#3, P¼0.02, siRNA#4)
by averages of 30% (S100A6 siRNAs#2) and 58.5% (S100A6
siRNAs#1). We also confirmed that depletion of S100A6 was
associated with a significant reduction in invasion through
matrigel-coated microporous membranes (Figure 4C), consistent
with the report by Ohuchida et al (2005). Of note, the effects of
annexin 2 on pancreatic cancer cell motility have never been
reported. We observed that transfection of Panc-1 cells with
an annexin 2-targeting siRNA (Figure 4D) was accompanied by a
50% decrease in the cell motility index compared with control
siRNA#1 as assessed by modified Boyden chamber assay. We
noted that 72h after transfection with the annexin 2-targeting
siRNA, there was also a 36% decrease in viable Panc-1 cell number,
compared with control siRNA#1 (n¼5 independent experiments,
P¼0.001).
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Figure 3 Knockdown of S100A6 was accompanied by loss of membranous annexin 2. (A) Western analysis of Panc-1 lysates 72h after transfection with
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sDepletion of S100A6 did not affect cell proliferation
To determine whether the reductions in cancer motility after
depletion of S100A6 expression might reflect losses in growth,
we undertook measurements of proliferation of cells 72h after
transfection with control- and S100A6-targeting siRNAs. The level
of [
3H]-thymidine incorporated into siRNA-treated cells (control
or targeted) was expressed as a proportion of that incorporated
in RISC-free control-treated cells. Depletion of S100A6 from
Panc-1 cells did not lead to significant reductions in [
3H]-
thymidine incorporation compared with control-siRNA-treated
cells (Figure 5A; P¼0.06, siRNA#1; P¼0.50, siRNA#2; P¼0.23,
siRNA#3; P¼0.27, siRNA#4). We also examined the effect of
depletion of S100A6 on cell proliferation by MTT assay.
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Figure 4 Expression of S100A6 and annexin 2 is associated with reduced pancreatic cancer cells motility. (A) Western analysis showing reduced S100A6
protein levels in Panc-1 cells 72h after treatment with four different S100A6-targeting siRNAs and two control siRNAs. Motility was significantly reduced
after S100A6 depletion compared with control-siRNA-transfected cells (n¼5 experiments performed in triplicate). (B) Depletion of S100A6 expression
inhibits wound healing. Western blot analysis of protein lysates from Panc-1 cells 72h after transfection with four S100A6-targeting and control siRNAs.
Histograms illustrate the motility index for wound healing assay using Panc-1 cell line. (C) Panc-1 invasiveness was significantly reduced in S100A6 siRNA-
transfected cells compared with control-siRNA-transfected cells (n¼6 experiments performed in triplicate). (D) Western analysis showing reduced annexin
2 protein levels in Panc-1 cells 72h after treatment with targeting siRNAs and control siRNAs. Motility was significantly reduced in the annexin 2-targeting
siRNA transfected Panc-1 cells compared with control-siRNA-transfected cells (n¼3 experiments performed in triplicate). Error bars represent the
standard error. The P-values were obtained using the Student’s paired t-test, two-tailed.
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depletion of S100A6 in Panc-1 cells (Figure 5B). Similarly,
depletion of S100A6 in MiaPaca-2 and Suit-2 cells was not
accompanied by any significant reductions in [
3H]-thymidine
incorporation (Supplementary Figure 4A and B; P¼0.33, both cell
lines) nor in MTT readings (Supplementary Figure 4C and D;
P¼0.32 and P¼76 for MiaPaca-2 and Suit-2, respectively).
DISCUSSION
Although S100A6 overexpression in pancreatic and other cancers,
including gastric (Yang et al, 2007), thyroid (Brown et al, 2006),
breast (Cross et al, 2005) and colorectal (Komatsu et al, 2000) has
been documented, its precise role in cancer is not known. In
pancreatic cancer, the expression of S100A6 appears to correlate
with aggressive disease in that high levels of tumour S100A6 are
associated with poorer outcome (Vimalachandran et al, 2005),
whereas pancreatic cancer cells depleted of S100A6 are less
invasive (Ohuchida et al, 2005). A link between S100A6 and colon
cancer invasion has also been suggested by the observation that
increased expression of S100A6 is found at the leading edges of
colon cancer tissues (Komatsu et al, 2000). However, the molecular
mechanism responsible for these effects has not been charac-
terised. Our proteomic-based approach to identify S100A6-binding
partners was performed with the aim of shedding light on S100A6
function in pancreatic cancer.
Our study identified the known S100A6-binding proteins,
tropomyosin b, annexin 11 and annexin 2 as well as novel binding
protein lamin B1, as candidate S100A6 interactors in pancreatic
cancer cells. The interaction and the colocalisation of S100A6
and tropomyosin have been documented (Golitsina et al, 1996;
Orre et al, 2007). Tropomyosins have been shown to regulate
microfilament organisation and actin dynamics (Boyd et al, 1995;
Gunning et al, 2008), with reduction in tropomyosin 1 levels
leading to anchorage independent growth (Boyd et al, 1995). Breen
et al observed disorganisation of tropomyosin associated cyto-
skeleton filament networks after depletion of S100A6 from
fibroblasts (Breen and Tang, 2003). Although we did not study
the interaction between tropomyosin and S100A6 here, it is
possible that the loss of motility observed after S100A6 depletion is
caused, at least in part, by an involvement of S100A6 with
tropomyosin. Annexin 11 is widely expressed and roles in cell
division (Farnaes and Ditzel, 2003) and cytokenesis (Tomas et al,
2004) have been reported. The binding of annexin 11 to S100A6
has been shown to take place in the nuclear envelope (Tomas and
Moss, 2003), where the complex may have a function in membrane
deconstruction during nuclear envelope breakdown in mitosis.
Lamin B1 is a major component of the nuclear lamina that
influences many aspects of cellular functions including prolifera-
tion, differentiation, transcription and apoptosis (Dechat et al,
2008). Although it has not been reported to bind S100A6, lamin B
has been shown to colocalise with S100A6 at focal points within the
nucleus (Tomas and Moss, 2003).
Annexin 2 is a member of a family of calcium-dependent,
phospholipid-binding proteins, possessing a number of intra-
cellular activities such as regulation of exocytosis, and extracellular
activities such as fibrinolysis through its interaction with tissue
plasminogen activator (tPA) (Gerke et al, 2005). It is present in
most cells as either a monomeric form within the cytoplasm or as
a tetramer, comprising two molecules of annexin 2 and two of
S100A10, localised to the plasma membrane-actin cytoskeleton
interface. Although S100A10 is the best-characterised binding
partner, annexin 2 has also been shown to interact with other S100
family members. For example, an interaction with S100A4
has been described (Semov et al, 2005). This interaction was
accompanied by accelerated tPA-mediated plasminogen activation
in solution as well as on endothelial cell surfaces (Semov et al,
2005), similar to that described for the Anx2/S100A10 complex.
Interaction with S100A6 has also been reported (Zeng et al, 1993).
Using matrix-immobilised S100A6, Zeng et al (1993) recovered
annexin 2 from a preparation of bovine heart proteins. Our
demonstration that S100A6 and annexin 2 coimmunoprecipitate
with either S100A6 or annexin 2 antibodies, along with their
colocalisation within the cytoplasm and membranes of pancreatic
cancer cells, suggest that S100A6 may be a significant annexin
2-binding partner in pancreatic cancer cells. Moreover, our
observation that high levels of S100A6 correlated with the
expression of membranous annexin 2 in patient tumours whilst
low S100A6 levels correlated with a lack of membranous annexin 2
suggests that S100A6 may affect the localisation of annexin 2
to membranes. This was further supported by the finding that
depletion of S100A6 in cultured pancreatic cancer cells was
found to result in diminished numbers of cells expressing
membranous annexin 2. A similar relationship between annexin
2 and S100A10 was reported by Deora et al (2004) who studied
the translocation of annexin 2 from the cytoplasm to the cell
surface of endothelial cells after the application of mild heat.
The authors found that depletion of S100A10 from endothelial cells
resulted in reduced surface expression of annexin 2, indicating
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sthat S100A10 expression was important for cell surface trans-
location of annexin 2.
The most striking phenotype of S100A6 depletion from
pancreatic cancer cells in our study was the dramatic loss of cell
motility, observed in both Boyden chamber and wound healing
assays. This loss of motility is likely to contribute to the reduced
invasion observed when S100A6 levels are depleted. Relatively little
is known about the contribution of S100A6 to cellular motility. The
only other published study, which to our knowledge examined the
effect of S100A6 on motility, showed a decrease in the motility of
one of three osteosarcoma cell lines after adenoviral-mediated
overexpression of S100A6 (Luu et al, 2005). Interestingly in
osteosarcoma, a trend was observed between decreased metastasis
and increased S100A6 staining, contrasting the findings in
melanoma and colorectal cancer (Maelandsmo et al, 1997;
Komatsu et al, 2000). Whether S100A6 contributes to pancreatic
cancer cell motility through interaction with annexin 2 is not yet
clear. However, the observed positive correlation in this study
between high S100A6 levels and the localisation of annexin 2 to the
plasma membrane in pancreatic cancer cells may have significance
with respect to the ability of these cells to move, as annexin 2 has
been implicated in the regulation of actin dynamics, cell spreading
and wound closure (Hayes et al, 2006; Babbin et al, 2007; de
Graauw et al, 2008). Hayes et al showed that annexin 2 was
concentrated in the dynamic actin-rich protrusions of motile cells
and that siRNA-mediated depletion of annexin 2 led to loss of
protrusive and retractile activity (Hayes et al, 2006). More recently,
Babbin et al (2007) observed that depletion of annexin 2 from
Caco-2 epithelial cells resulted in reductions in cell spreading and
wound closure. Finally, the work of de Graauw et al (2008) pointed
towards the phosphorylation of annexin 2 as a key event in the
remodelling of the actin cytoskeleton during cell spreading. Thus,
if high levels of S100A6 promote or facilitate annexin 2 trans-
location to the cell membrane, this may positively enhance cell
motility. However, we cannot rule out the possibility that the
relationship between membranous expression of annexin 2 and
S100A6 level is a consequence, rather than a cause, of the effect of
S100A6 on motility. In addition, the interaction between annexin 2
and S100A6 may contribute to increased tPA activity, which could
lead to a variety of effects, potentially including increased cell
motility (Ortiz-Zapater et al, 2007; Sharma and Sharma, 2007).
In summary, our study has provided insight into candidate
S100A6-binding partners in pancreatic cancer and has shown
a positive relationship between the cellular levels of S100A6 and
the localisation of annexin 2 to the cell membrane. Finally, our
findings provide new insight into S100A6 function, namely that it
promotes pancreatic cancer cell motility.
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